Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

    Powerful effects seen in all subjects including those with low HDL -
    representing a majority of myocardial infarct patients

    TSX Exchange Symbol: RVX

CALGARY, Sept. 29 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that results from the Company's Phase 1b/2a clinical trial have met and exceeded expectations by successfully concluding the drug, RVX-208, is safe and tolerable. Most importantly RVX-208 has met its primary endpoint to increase the production of plasma ApoA-I, the key cardioprotective protein in high-density lipoprotein (HDL), often referred to as "good" cholesterol. ApoA-I is generally endorsed as a key protective factor against atherosclerosis and cardiovascular disease with 40% of all first heart attack patients having low ApoA-I.

Resverlogix's Phase 1b/2a study tested RVX-208 for 28 days in three different dosing arms. The most pronounced results were demonstrated among those subjects with low HDL cholesterol levels. Low HDL is an important risk factor in coronary and cardiovascular disease patients. Resverlogix will continue to build upon its world leading position in development of novel small molecules that increase ApoA-l production and reverse cholesterol transport (RCT) markers in patients with high vascular risk profiles. RCT is a path by which cholesterol on the arterial wall is transported back to the liver by ApoA-I lipid complexes for excretion. Additional analysis was performed on other key RCT markers which achieved high levels of statistical significance. The Company has established a dosing range that it deems will be safe, well tolerated and effective for Phase 2 intravascular ultrasound (IVUS) development trials.

"The range of increase in ApoA-l production of all subjects, but in particular low HDL subjects over placebo demonstrated in this study is one of the most significant pieces of data for RVX-208. We have excee
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/1/2014)... , Cambridge Semantics, the leading provider of Smart ... announced its participation in the 2014 Big Data Leaders ... provide semantic linkage and meaning to Big Data to ... diverse data. Ben Szekely, vice president and founding engineer ... sciences data lake” and an approach for collecting and ...
(Date:10/1/2014)... Weighing applications in pharmaceutical manufacturing ... product. However, while the pharmaceutical industry is one ... Good Manufacturing Practices (GMP) usually provide only broad ... to interpret these guidelines and assess process risks ... TOLEDO experts have created a new white paper, ...
(Date:10/1/2014)... The participants committed to not only creating ... own time adjusting, tweaking and testing virtual models and ... for judging. , “I enjoyed being involved as a ... “The entries showed a commendable range exploring the technical ... print medium and the creativity of the contestants.” , ...
Breaking Biology Technology:Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Comply with Weighing-Related Regulations in Pharma Manufacturing 2Array Architects Challenges Staff to Create with 3D Printer 2
... ANTONY, France, July 10 , - 1st Half-Year Sales Up 16%, - Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal,to)12%, EUR millions ... 07/06 2008 08/07 ... ... Europe (1) 20.5 72 23.2 72 13 26.8 71 ...
... July 10 Today,s Pharmaceutical Research,and ... to end the practice,of providing non-educational ... toward,enhancing the value of the physician/industry ... CMR Institute, a leading non-profit,organization dedicated ...
... July 10 Quest Diagnostics,Incorporated (NYSE: DGX ), ... announced today that its second-quarter,2008 results will be made ... that it will hold its quarterly conference call with ... on that day., The public may access the ...
Cached Biology Technology:Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth 2CMR Institute: Education Key to Physician/Representative Relationship 2Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
(Date:9/30/2014)... some hope: A new research report published in October ... , explains how scientists developed a synthetic version of ... development in human and mouse eggs similar to the ... during fertilization. , "We believe that the results of ... understanding of human fertilization by providing a precise answer ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may ... week in mBio , the online open-access journal of ... from the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal ... ramosum gained weight when fed a high-fat diet. Mice ... obese even when consuming a high-fat diet, and mice that ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... food safety and traceability will be showcased at a ... The Food Integrity and Traceability Conference will take place ... leading scientists, food standards regulators and agri-food producers from ... Institute for Global Food Security and from across the ...
... BRCA2 gene have a worse prognosis and lower survival rates ... This is the main conclusion to come out of a ... Oncology , in which David Olmos, Head of the Prostate ... National Cancer Research Centre (CNIO), has taken part in, along ...
... making the disease difficult to study. However, K9 bone ... the disease, and over 10,000 canine patients develop the ... Cancer Center and the Colorado State University Flint Animal ... used easily available K9 osteosarcoma samples to discover a ...
Cached Biology News:International conference will put agri-food supply chain under the microscope 2First genetic factor in prostate cancer prognosis identified 2AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... Cyclin D2 is a G1 cyclin ... strong candidate for a proto-oncogene. cyclin ... cdk4 and/or cdk6. Species Reactivity: Human, ... NeoMarkers DCS-3.1 MAb is particularly well suited ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: